Table 3.
Results of the adjusted base-case and subgroup analyses
| Lamotrigine | Levetiracetam | Zonisamide | |
|---|---|---|---|
| Base-case all participants (n=990) | |||
| Total costs (£) | 4042 (3626–4983) | 5104 (4450–6141) | 5400 (4659–6770) |
| QALYs | 1·605 (1·547–1·651) | 1·474 (1·393–1·523) | 1·502 (1·418–1·566) |
| Net health benefit at £20 000 per QALY (QALYs) | 1·403 (1·319–1·458) | 1·222 (1·110–1·283) | 1·232 (1·112–1·307) |
| Children aged <16 years (n=155) | |||
| Total costs (£) | 5076 (3815–7219) | 4972 (3739–6840) | 4638 (3826–6974) |
| QALYs | 1·551 (1·432–1·638) | 1·556 (1·397–1·618) | 1·508 (1·381–1·610) |
| Net health benefit at £20 000 per QALY (QALYs) | 1·297 (1·127–1·412) | 1·307 (1·097–1·394) | 1·277 (1·068–1·390) |
| Adults and adolescents aged ≥16 years (n=835) | |||
| Total costs (£) | 3844 (3379–4478) | 5178 (4435–6223) | 5509 (4610–6866) |
| QALYs | 1·612 (1·554–1·661) | 1·466 (1·381–1·518) | 1·508 (1·412–1·569) |
| Net health benefit at £20 000 per QALY (QALYs) | 1·420 (1·346–1·475) | 1·207 (1·095–1·280) | 1·227 (1·101–1·320) |
Data are mean (97·5% central range). QALY=quality-adjusted life-years.